NCT03859739View on ClinicalTrials.gov

Safety, Tolerability, Pharmacokinetics, and Anti-Retroviral Activity of MK-8558 Monotherapy in Anti-Retroviral-Naïve HIV-1 Infected Participants (MK-8558-002)

PHASE1CompletedINTERVENTIONAL
Enrollment

21

Participants

Timeline

Start Date

April 26, 2019

Primary Completion Date

May 29, 2020

Study Completion Date

May 29, 2020

Conditions
HIV-1 Infection
Interventions
DRUG

MK-8558

Single dose of MK-8558 administered as a tablet at a dose up to 1600 mg.

Trial Locations (2)

10117

Charite Research Organisation GmbH ( Site 0001), Berlin

021105

Matei Bals Infectious Diseases Institute ( Site 0002), Bucharest

All Listed Sponsors
lead

Merck Sharp & Dohme LLC

INDUSTRY

NCT03859739 - Safety, Tolerability, Pharmacokinetics, and Anti-Retroviral Activity of MK-8558 Monotherapy in Anti-Retroviral-Naïve HIV-1 Infected Participants (MK-8558-002) | Biotech Hunter | Biotech Hunter